Eli Lilly, Nordisk accused of limiting US competition for GLP-1 drugs
MLex Summary: Eli Lilly and Novo Nordisk have been accused in a US complaint of illegally stifling competition from compounding pharmacies on the sale of glucagon-like-peptide-1 agonists (GLP-1 drugs). According to...To view the full article, register now.
Already a subscriber? Click here to view full article